Jefferies Financial Group Raises Compass Therapeutics (NASDAQ:CMPX) Price Target to $8.00

Compass Therapeutics (NASDAQ:CMPX) had its target price hoisted by equities researchers at Jefferies Financial Group from $7.00 to $8.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Jefferies Financial Group’s target price suggests a potential upside of 119.18% from the company’s previous close.

CMPX has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $5.00 to $4.00 in a research report on Friday, November 15th. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $11.17.

Compass Therapeutics Trading Down 6.4 %

CMPX opened at $3.65 on Monday. The stock has a market cap of $502.20 million, a PE ratio of -9.86 and a beta of 1.17. Compass Therapeutics has a 1 year low of $0.76 and a 1 year high of $4.08. The stock’s 50 day simple moving average is $2.16 and its 200-day simple moving average is $1.76.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Equities analysts forecast that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Rovin Capital UT ADV bought a new position in shares of Compass Therapeutics during the third quarter worth about $25,000. Independent Advisor Alliance acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $26,000. Intech Investment Management LLC acquired a new stake in shares of Compass Therapeutics in the third quarter valued at approximately $30,000. XTX Topco Ltd acquired a new stake in Compass Therapeutics during the 3rd quarter worth approximately $37,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Compass Therapeutics during the 2nd quarter worth approximately $41,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.